GlassScriptPhysician profile
Leigh A Minchew
NPI 1265732994
$2,500.47
in general payments reported to CMS, 2019-2025
29 companies · $361 in 2025
The $361 reported for 2025 was more than what 79% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.23 · 2022: $565 · 2023: $469 · 2024: $1,019 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,850.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $365.08 | 2022-2025 | Lynparza, Calquence |
| Novartis Pharmaceuticals Corporation | $183.98 | 2022-2025 | |
| Glaxosmithkline, LLC. | $154.82 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Novo Nordisk INC | $151.43 | 2021-2024 | Wegovy |
| Pfizer INC. | $136.74 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $130.96 | 2024 | Soliris |
| Janssen Scientific Affairs, LLC | $127.88 | 2023 | Tecvayli, Darzalex |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2024 | Uptravi, Opsumit |
| Jazz Pharmaceuticals INC. | $122.11 | 2022 | |
| Myriad Genetic Laboratories, INC. | $116.55 | 2024 | Myrisk |
| Neurelis, INC. | $110.01 | 2022 | |
| Incyte Corporation | $102.46 | 2022-2025 | Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $95.31 | 2022-2023 | Keytruda |
| Janssen Biotech, INC. | $89.86 | 2023-2024 | Erleada, Akeega, Rybrevant |
| Daiichi Sankyo INC. | $72.66 | 2022-2025 | Enhertu, Injectafer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $65.39 | 2023-2024 | Iclusig, Alunbrig |
| Vertex Pharmaceuticals Incorporated | $44.55 | 2024 | |
| Genzyme Corporation | $36.47 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $36.25 | 2024-2025 | Monoferric, Cosela |
| Adc Therapeutics America, INC. | $35.31 | 2023-2024 | |
| Amgen INC. | $30.13 | 2022 | |
| Emd Serono, INC. | $27.95 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $27.85 | 2025 | Libtayo |
| Dexcom, INC. | $24.46 | 2024 | Dexcom G6 Transmitter |
| Beigene USA, INC. | $20.92 | 2024 | Tevimbra |
| Abbvie INC. | $18.44 | 2023 | |
| Tersera Therapeutics LLC | $17.92 | 2023 | Zoladex |
| E.R. Squibb & Sons, L.L.C. | $15.96 | 2022 | |
| Apellis Pharmaceuticals, INC. | $14.02 | 2023 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Minchew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.